🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Matches test film-coated tablets, Wakix 4.5 mg film-coated tablets, Wakix 18 mg film-coated tablets

    Bioprojet Pharma

    Narcolepsy

    phase 3 small molecule active

    1 trial

  2. Matching Placebo for Upadacitinib

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  3. Matching placebo MGL-3196 60 mg film-coated tablet, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 100 mg film-coated tablet., MGL-3196 60 mg oral, MGL-3196 100 mg oral, MGL-3196 80 mg oral

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  4. Matching placebo for BAY 597939 2.5 mg filmcoated tablets, Rivaroxaban 2.5 mg

    The George Institute

    Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.

    phase 3 small molecule active

    1 trial

  5. Matching placebo for Tezepelumab solution for injection, TEZEPELUMAB

    AstraZeneca AB

    Severe Uncontrolled Asthma Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that asthma attacks are still occurring despite the use of other available treatments

    phase 3 small molecule active

    1 trial

  6. Matching placebo tablet, JNJ-67953964

    Janssen-Cilag International N.V.

    Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia

    phase 3 small molecule active

    1 trial

  7. Matching placebo tablet, JNJ-67953964

    Janssen-Cilag International N.V.

    Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia

    phase 3 small molecule active

    1 trial

  8. Melflufen

    Oncopeptides AB (publ)

    Multiple Myeloma

    phase 3 small molecule terminated

    1 trial

  9. Metformin

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  10. Metformin on top of intensive insulin therapy

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  11. Metformin plus pioglitazone

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  12. Methylprednisolon acis 250 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Ocrevus 300 mg concentrate for solution for infusion, Gilenya 0.25 mg hard capsules, Placebo for FINGOLIMOD, Placebo for Ocrelizumab, Gilenya 0.25 mg hard capsules, Reisetabletten AL Dimenhydrinat 50 mg pro Tablette, Methylprednisolon acis 1000 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules

    Hoffmann-La Roche

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  13. Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Diphenhydramine Hydrochloride Tablets 50 mg

    Hoffmann-La Roche

    Progressive multiple sclerosis (PMS)

    phase 3 small molecule active

    1 trial

  14. Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg

    Hoffmann-La Roche

    Multiple sclerosis (MS)

    phase 3 small molecule active

    1 trial

  15. Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Placebo of methylprednisolone (glucose 5%), placebo of prednisone, PREDNISONE ARROW 20 mg, comprimé sécable

    Pari Pharma GmbH

    Patients presenting with acute myocarditis proven by cardiac magnetic resonance imaging (CMRi) or by histological evidence on endomyocardial biopsy (EMB)

    phase 3 small molecule active

    1 trial

  16. Mezagitamab

    Takeda

    Chronic Primary Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  17. Mezagitamab

    Takeda

    Immune Thrombocytopenic Purpura (ITP)

    phase 3 small molecule active

    2 trials

  18. Mezagitamab, Mezagitamab placebo-matching injection administered SC

    Takeda

    IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Berger's disease)

    phase 3 small molecule active

    1 trial

  19. Mezagitamab, Placebo matching for Mezagitamab

    Takeda

    Chronic Primary Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  20. Mibavademab

    Regeneron UK Limited

    Monogenic Obesity

    phase 3 small molecule active

    1 trial

  21. Mibavademab

    Regeneron UK Limited

    Generalized Lipodystrophy

    phase 3 small molecule active

    2 trials

  22. Micofenolato de mofetil Generis 250 mg Cápsulas, Inflectra 100 mg powder for concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Gemcitabine 100 mg/ml Concentrate for Solution for Infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Oxaliplatine Accord 5 mg/ml concentraat voor oplossing voor infusie

    AstraZeneca AB

    Advanced Biliary Tract Cancers

    phase 3 small molecule active

    1 trial

  23. Migalastat Hydrochloride Dispersible Tablet

    AMICUS THERAPEUTICS PTY LTD

    Fabry disease

    phase 3 small molecule active

    1 trial

  24. Mirabegron

    Astellas Pharma Inc

    Overactive Bladder (OAB)

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources